



# Prognostic Importance of Multiple Nutrition Screening Indexes for 1-Year Mortality in Hospitalized Acute Decompensated Heart Failure Patients

Tomonobu Takikawa, MD; Takuya Sumi, MD; Kunihiro Takahara, MD;  
Yoshihiro Kawamura, MD; Shioh Ohguchi, MD; Mitsutoshi Oguri, MD, PhD;  
Hideki Ishii, MD, PhD; Toyooki Murohara, MD, PhD

**Background:** The purpose of the study was to evaluate the impact of nutritional status on 1-year mortality in hospitalized patients with acute decompensated heart failure (ADHF).

**Methods and Results:** We enrolled 457 hospitalized ADHF patients. Previously established objective nutritional indexes (controlling nutritional status [CONUT], prognostic nutritional index [PNI], geriatric nutritional risk index [GNRI], and subjective global assessment [SGA]) were evaluated at hospital admission. Malnutrition was defined as CONUT score  $\geq 5$ , PNI score  $< 38$ , GNRI score  $< 92$ , and SGA scores B and C. The frequencies of malnutrition based on CONUT, PNI, GNRI, and SGA were 31.5%, 21.4%, 44.9%, and 27.8%, respectively. All indexes were related to the occurrence of 1-year mortality on univariate Cox regression analysis ( $P < 0.05$ ). We constructed a reference model using age, body mass index, systolic blood pressure, sodium concentration, and renal function on multivariable Cox regression analysis. Adding SGA to the reference model significantly improved both net reclassification improvement (NRI) and integrated discrimination improvement (0.344,  $P = 0.002$ ; 0.012,  $P = 0.049$ ; respectively). Other indexes (CONUT, PNI, and GNRI scores) significantly improved NRI (0.254,  $P = 0.019$ ; 0.273,  $P = 0.013$ ; 0.306,  $P = 0.006$ ; respectively).

**Conclusions:** Nutritional screening assessed at hospital admission was appropriate for the prediction of 1-year mortality in hospitalized patients with ADHF.

**Key Words:** Acute heart failure; Nutrition assessment; Prognosis

The prevalence of heart failure increases with age.<sup>1</sup> In Japan, the number of elderly people is increasing rapidly, and the prevalence of acute decompensated heart failure (ADHF) is steadily increasing.<sup>2</sup> Malnutrition is an important factor in the exacerbation of chronic heart failure.<sup>3,4</sup> Regarding the relationship between heart failure and malnutrition, intestinal ischemia affected by low output syndrome causes absorption disorder and decreases peristalsis. Simultaneously, intestinal edema affected by gastrointestinal congestion causes abdominal fullness and loss of appetite, which decreases oral intake despite hypermetabolic conditions due to chronic inflammation in patients with heart failure.<sup>3</sup> Consequently, chronic heart failure results in malnutrition.<sup>5</sup> Taken together, nutrition status has been extensively examined in patients with chronic heart failure. There are several reports on CHF patients, while few studies have evaluated the relationship between clinical prognosis and nutritional status in ADHF. In

addition, appropriate nutrition measurement in ADHF has not been well evaluated. Therefore, the purposes of the present study were to evaluate the impact of nutritional status on 1-year mortality and to assess appropriate nutrition measurements in hospitalized patients with ADHF.

## Methods

We enrolled 457 consecutive patients with ADHF who were admitted to Kasugai Municipal Hospital, Aichi, Japan, between November 2009 and August 2015. For patients with multiple admissions, the first eligible hospitalization for ADHF was evaluated. We excluded patients with ADHF caused by acute coronary syndrome or malignancy.


Medical records were reviewed to assess clinical characteristics (age, gender, previous medical history, etiology, comorbidities, and laboratory data) and 1-year mortality

Received November 27, 2018; revised manuscript received December 5, 2018; accepted December 6, 2018; J-STAGE Advance Publication released online January 11, 2019 Time for primary review: 1 day

Department of Cardiology, Graduate School of Medicine, Nagoya University, Nagoya (T.T., H.I., T.M.); Department of Cardiology, Ichinomiya Municipal Hospital, Ichinomiya (T.S.); and Department of Cardiology, Kasugai Municipal Hospital, Kasugai (K.T., Y.K., S.O., M.O.), Japan

Mailing address: Hideki Ishii, MD, PhD, FAHA, FESC, FJCS, Department of Cardiology, Graduate School of Medicine, Nagoya University, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560, Japan. E-mail: hkishii@med.nagoya-u.ac.jp

ISSN-2434-0790 All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: cr@j-circ.or.jp



rates collected from outpatient visits. All patients were followed up for 1 year and we examined the association between 1-year mortality and nutrition status in patients with ADHF retrospectively. We compared all data according to survival status.

The study protocol complied with the Declaration of Helsinki and was approved by the Committees on the Ethics of Human Research of Kasugai Municipal Hospital. Written informed consent was obtained from each patient.

Body mass index (BMI) was calculated using the following formula:  $\text{BMI} = \text{mass (kg)} / \text{height}^2 (\text{m}^2)$ . We defined anemia as serum hemoglobin  $<13$  mg/dL in men and  $<12$  mg/dL in women.<sup>6</sup>

Previously established objective nutritional indexes (controlling nutritional status [CONUT], prognostic nutritional index [PNI], geriatric nutritional risk index [GNRI], and subjective global assessment [SGA]) were evaluated at hospital admission. The control criteria are shown in **Figure 1**. CONUT score was determined using serum albumin level, total cholesterol level, and total lymphocyte count.<sup>7</sup> The formula was as follows: CONUT score = albumin score ( $\geq 3.5$  g/dL, 0 points; 3.0–3.4 g/dL, 2 points; 2.5–2.9 g/dL, 4 points;  $<2.5$  g/dL, 6 points) + total lymphocyte score ( $\geq 1,600$  /mL, 0 points; 1,200–1,599 /mL, 1 point; 800–1,199 /mL, 2 points;  $<800$  /mL, 3 points) + total cholesterol score ( $\geq 180$  mg/dL, 0 points; 140–179 mg/dL, 1 point; 100–139 mg/dL, 2 points;  $<100$  mg/dL, 3 points). PNI score was calculated using serum albumin level and total lymphocyte count.<sup>8</sup> The formula was as follows:  $\text{PNI} = 10 \times \text{serum albumin concentration (g/dL)} + 0.005 \times \text{total lymphocyte count (/}\mu\text{L)}$ . GNRI score was calculated using serum albumin level, and body weight and height.<sup>9</sup> The formula was as follows:

$\text{GNRI} = 14.89 \times \text{serum albumin (g/dL)} + 41.7 \times (\text{actual body weight/ideal body weight})$ . Actual body weight/ideal body weight was set to 1 when the patient's body weight exceeded the ideal body weight. The ideal body weight in the present study was calculated using  $\text{BMI } 22 \text{ kg/m}^2$ . SGA score was based on history and physical examination: patients were subjectively rated as well nourished (A), moderately malnourished (B), or severely malnourished (C).<sup>10</sup> The examiner asked every patient about any involuntary weight loss and/or changes in dietary intake in the past 6 months and 2 weeks, the presence of any gastrointestinal symptoms for  $>2$  weeks (nausea, vomiting, diarrhea, and anorexia), and his/her performance status. Physical examination assessed the severity of subcutaneous fat loss, muscle wasting, and ankle and sacral edema, as well as ascites on a 4-point scale (0–3).

Malnutrition was defined as CONUT score  $\geq 5$ , PNI score  $<38$ , GNRI score  $<92$ , and SGA scores B and C.

### Statistical Analysis

The distribution of continuous variables was examined using the Shapiro-Wilk test. Continuous variables are expressed as median (IQR), and categorical variables as n (%). Comparison of continuous variables was performed using the Student's t-test or Mann-Whitney U-test. Categorical variables were analyzed using the chi-squared test or Fisher's exact probability test. All baseline variables with  $P < 0.05$  on univariate Cox regression analysis were entered into multivariate Cox regression analysis to determine independent predictors of 1-year mortality.

We then defined the baseline model, which included factors significantly and independently associated with

**Table 1. Subject Characteristics vs. Survival Status**

Parameter	Total	Died	Survived	P-value
No. subjects (n)	457	81	376	
Age (years)	79.0 (70.0–86.0)	84.0 (78.5–90.0)	78.0 (69.0–84.0)	<0.001*
Male gender	53.4	48.2	54.5	0.298
BMI (kg/m <sup>2</sup> )	22.4 (19.9–25.1)	20.6 (18.8–22.8)	22.7 (20.4–25.6)	<0.001*
Current or former smoking (%)	43.5	38.3	44.7	0.289
SBP (mmHg)	156 (129–188)	137 (120–175)	161 (133–189)	<0.001*
DBP (mmHg)	88 (72–107)	78 (60–94)	91 (74–110)	<0.001*
Heart rate (beats/min)	102 (86–125)	98 (81–114)	105 (87–125)	0.045*
Etiology (%)				
Ischemic heart disease	31.5	32.1	31.4	0.900
Valvular heart disease	12.4	16.1	11.7	0.297
Cardiomyopathy	13.1	13.6	13.0	0.895
Hypertension	21.4	12.4	23.4	0.021*
Arrhythmia	12.0	7.4	13.0	0.137
Serum TC (mg/dL)	157 (132–821)	147 (121–176)	159 (135–184)	0.009*
Serum TG (mg/dL)	74 (55–102)	79 (55–105)	74 (55–99)	0.797
Serum HDL-C (mg/dL)	41 (33–51)	40 (30–46)	42 (34–52)	0.017*
Serum LDL-C (mg/dL)	94 (71–116)	86 (58–112.3)	95 (73–117)	0.017*
FPG (mg/dL)	134 (108–188)	129 (110–190)	135 (108–188)	0.998
Blood HbA <sub>1c</sub> (NGSP, %)	5.9 (5.4–6.7)	5.7 (5.2–6.7)	5.9 (5.5–6.7)	0.051*
BUN (mg/dL)	24.9 (17.4–35.3)	33.3 (24.1–51.3)	23.4 (16.7–33.0)	<0.001*
Serum sodium (mEq/L)	141 (138–143)	139 (137–142)	141 (139–143)	<0.001*
Serum potassium (mEq/L)	4.3 (3.8–4.7)	4.5 (4.1–5.0)	4.2 (3.8–4.6)	<0.001*
Serum creatinine (mg/dL)	1.1 (0.8–1.7)	1.4 (1.0–2.5)	1.1 (0.8–1.6)	<0.001*
eGFR (mL/min/1.73 m <sup>2</sup> )	45.3 (25.9–63.5)	30.9 (15.5–54.4)	47.0 (27.6–64.5)	<0.001*
Serum uric acid (mg/dL)	7.2 (5.5–8.8)	7.4 (5.5–9.9)	7.2 (5.5–8.6)	0.221
Serum albumin (mg/dL)	3.6 (3.2–3.9)	3.5 (3.1–3.7)	3.6 (3.2–3.9)	0.009*
Serum CRP (mg/L)	7.5 (2.2–24.7)	7.4 (1.8–47.5)	7.5 (2.2–21.8)	0.397
BNP (pg/mL)	756 (410–1,405)	971 (507–1,623)	701 (389–1,355)	0.038*
WBC (10 <sup>3</sup> /μL)	7.9 (6.1–10.6)	7.8 (6.5–10.8)	8.0 (6.1–10.5)	0.766
Total lymphocytes (/μL)	1,332 (868–1,996)	1,071 (630–1,656)	1,416 (910–2,036)	0.001*
Hb (mg/dL)	11.7 (10.1–13.5)	10.4 (9.1–12.0)	11.9 (12.0–13.8)	<0.001*
Anemia	62.9	84.0	58.4	<0.001*
LVEF (%)	50.0 (39.0–62.8)	54.5 (43.0–60.8)	49.8 (38.0–63.0)	0.319
Comorbidity (%)				
Type 2 DM	39.6	40.7	39.4	0.818
Dyslipidemia	23.4	21.0	23.9	0.566
Hypertension	63.2	59.3	64.1	0.415
AF or AFI	26.3	25.9	26.3	0.940


Data given as % or median (IQR). \*P<0.05. AF, atrial fibrillation; AFI, atrial flutter; BMI, body mass index; BNP, brain-type natriuretic peptide; BUN, blood urea nitrogen; CRP, C-reactive protein; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; Hb, hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; NGSP, National Glycohemoglobin Standardization Program; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; WBC, white blood cells.

1-year mortality on multivariate Cox regression analysis. Finally, we calculated the C-index, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Differences were considered statistically significant at P<0.05. Statistical analysis was performed using IBM SPSS Statistics 18.0 (IBM, Somers, NY, USA), R version 3.2.1 (R Project for Statistical Computing), and JMP version 5.1 (SAS Institute, Cary, NC, USA).

## Results

Baseline patient characteristics are listed in **Table 1**.

Eighty-one patients died (17.7%) within 1 year. The rate of cardiovascular and non-cardiovascular death was 70.4% and 29.6%, respectively. Seventy-nine patients (17.3%) were re-admitted due to heart failure within 1 year. The average age was 79 years (IQR, 70–86 years), and 53.4% of the patients were male. Patients who died were significantly older (P<0.001), whereas BMI, systolic blood pressure (SBP), diastolic blood pressure, heart rate, and the frequency of hypertensive heart disease were significantly higher in patients who survived (P<0.05). With regard to laboratory data, blood urea nitrogen, serum potassium, serum creatinine, and brain-type natriuretic peptide were



significantly higher in patients who died ( $P<0.05$ ), whereas serum sodium, estimated glomerular filtration rate (eGFR), serum albumin, serum total cholesterol, and hemoglobin, and total lymphocyte count were significantly lower in patients who died ( $P<0.05$ ). Left ventricular ejection fraction and the frequency of systolic dysfunction were not different between the 2 groups. The prevalence of atrial fibrillation or atrial flutter was 25.9% in patients who died, 26.3% in patients who survived, and there was no significant difference between the 2 groups. The use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers,  $\beta$ -blocker, aldosterone blocker, and diuretics at hospital admission was similar between the 2 groups (Supplementary Table). The frequency of malnutrition based on each nutrition index is shown in Figure 2. Malnutrition was observed in 31.5% based on CONUT score, 21.4% based on PNI score, 44.9% based on GNRI score, and 27.8% based on SGA score.

We compared malnutrition between the 2 groups (Figure 3). In patients who died, malnutrition was observed in 42.0% based on CONUT score, 32.1% based on PNI score, 60.5% based on GNRI score, and 45.7% based on SGA score. In patients who survived, malnutrition was observed in 29.3% based on CONUT score, 19.2% based on PNI score, 41.5% based on GNRI score, and 23.9% based on SGA. In all indexes, malnutrition was significantly more prevalent in patients who died than in those who survived ( $P<0.05$ ; Figure 4).


We examined predictors of 1-year mortality on univariate and multivariate Cox regression analyses (Table 2). Variables with  $P<0.05$  on univariate Cox regression analysis were included in the multivariate Cox regression analysis. Age, BMI, SBP, eGFR, and serum sodium were significantly associated with 1-year mortality in this study. Therefore, we defined the baseline model using age, BMI, SBP, eGFR, and serum sodium.


Finally, we calculated the C-index, NRI, and IDI (Table 3). Adding each nutrition index to the baseline model improved the prediction of 1-year mortality compared with the baseline model alone ( $P<0.05$ ). The addition of CONUT, PNI, or GNRI score significantly improved NRI ( $P<0.05$ ). The addition of SGA significantly improved both NRI and IDI ( $P<0.05$ ).

## Discussion

The principal findings of this study were as follows: (1) malnutrition was a predictor of 1-year mortality even in patients with ADHF (similar to the results obtained in a previous study involving patients with chronic heart failure); and (2) adding each nutrition index improved the prediction of 1-year outcome in hospitalized patients with ADHF.

Low BMI or sarcopenia is related to poor prognosis in patients with heart failure.<sup>11–14</sup> In contrast, some reports suggest that the severity of chronic disease contributes to frailty status.<sup>15</sup> The frailty cycle centered on sarcopenia is attracting attention with regard to chronic diseases that





may affect elderly individuals. Regarding the relationship between heart failure and nutrition, malnutrition was observed in 25% of hospitalized patients with chronic heart failure.<sup>16</sup> Although the present study also noted variation, the percentage of malnutrition was >20% for each nutrition index.

In the present study patients with malnutrition had a poorer prognosis than the subjects with adequate nutritional status. In short, malnutrition increased the risks of readmission and mortality due to heart failure.<sup>17,18</sup>

Heart failure is a progressive disease that worsens with repeated exacerbation and readmission, regardless of treatment. In this study, nutrition and heart failure were involved even in the acute phase of heart failure.

Plasma albumin concentration is controlled by several factors, including rate of albumin synthesis, catabolic rate, albumin distribution, and exogenous albumin loss.<sup>19–21</sup> Hypoalbuminemia is an independent prognostic predictor in patients with chronic heart failure.<sup>16</sup> Lymphocyte count reflects inflammation and the stress response.<sup>22</sup> Lower lymphocyte count independently predicts clinical events in patients with chronic heart failure.<sup>23</sup> Total cholesterol level reflects lipid metabolism and has also been reported as an independent predictor of clinical events in patients with

chronic heart failure.<sup>24</sup> CONUT score is a nutritional screening tool used in various fields.<sup>7</sup> It is a screening tool used to comprehensively evaluate protein metabolism, immunity, and lipid metabolism. PNI is a nutritional screening tool that has been proposed in the field of surgery to evaluate nutritional status and immunity.<sup>8</sup> GNRI is often used for nutritional screening in elderly people.<sup>9</sup> It is also used for nutritional screening in patients undergoing hemodialysis.<sup>25</sup> These nutrition indexes include albumin level, total cholesterol level, and lymphocyte count proportions to some degree. Objective nutrition indexes may also provide additional prognostic information in patients with chronic heart failure.<sup>26</sup> Therefore, we thought that screening using these indexes at the time of admission would be useful to predict 1-year mortality in this study.

SGA is a nutrition screening tool that consists of 5 interviews and 5 physical examinations including both subjective and objective assessments. SGA has been used in patients of almost all ages and can also evaluate the risk of delayed healing or infection.<sup>10</sup> In addition, SGA is a subjective comprehensive evaluation that has a significant correlation with albumin level, total cholesterol level, and total lymphocyte count.<sup>27</sup> SGA is also related to sarcopenia.<sup>28,29</sup> In addition, sarcopenia has also been reported as



Parameter	Univariate analysis		Multivariate analysis	
	P-value	HR (95% CI)	P-value	HR (95% CI)
Age (years)	<0.001*	1.06 (1.04–1.09)	0.001*	1.04 (1.02–1.07)
Male gender (%)	0.249	0.88 (0.71–1.09)		
BMI (kg/m <sup>2</sup> )	<0.001*	0.86 (0.80–0.91)	<0.001*	0.89 (0.83–0.96)
SBP (mmHg)	<0.001*	0.99 (0.98–1.00)	0.005*	0.99 (0.99–1.00)
DBP (mmHg)	<0.001*	0.98 (0.97–0.99)		
Heart rate (beats/min)	0.063	0.99 (0.98–1.00)		
Serum TC (mg/dL)	0.002*	0.99 (0.98–1.00)		
Serum TG (mg/dL)	0.617	1.00 (0.99–1.00)		
Serum HDL-C (mg/dL)	0.005*	0.97 (0.95–0.99)		
Serum LDL-C (mg/dL)	0.004*	0.99 (0.98–1.00)		
FPG (mg/dL)	0.866	1.00 (1.00–1.00)		
Blood HbA <sub>1c</sub> (NGSP, %)	0.062	0.78 (0.57–1.01)		
BUN (mg/dL)	<0.001*	1.04 (1.03–1.05)		
Serum sodium (mEq/L)	0.025*	0.95 (0.92–0.99)	0.044*	0.96 (0.92–1.00)
Serum potassium (mEq/L)	<0.001*	1.62 (1.23–2.10)		
Serum creatinine (mg/dL)	<0.001*	1.23 (1.11–1.35)		
eGFR (mL/min/1.73 m <sup>2</sup> )	<0.001*	0.98 (0.97–0.99)	0.007*	0.99 (0.97–1.00)
Serum uric acid (mg/dL)	0.091	1.08 (0.99–1.18)		
Serum albumin (mg/dL)	0.005*	0.55 (0.37–0.83)		
Serum CRP (mg/L)	0.092	1.05 (0.99–1.10)		
BNP (pg/mL)	0.036*	1.00 (1.00–1.00)		
WBC (10 <sup>3</sup> /μL)	0.216	1.00 (1.00–1.00)		
Total lymphocytes (/μL)	0.024*	1.00 (1.00–1.00)		
Hb (mg/dL)	<0.001*	0.79 (0.72–0.87)		
Anemia (%)	<0.001*	1.85 (1.40–2.55)	0.079	1.30 (0.97–1.82)
LVEF (%)	0.217	1.01 (0.99–1.03)		

\*P<0.05. Abbreviations as in Table 1.

Parameter	C-index (95% CI)	P-value	NRI	P-value	IDI	P-value
Baseline model	0.769 (0.716–0.823)	Ref.		Ref.		Ref.
Baseline+CONUT score	0.771 (0.717–0.825)	0.743	0.254	0.019*	0.003	0.192
Baseline+PNI	0.772 (0.718–0.826)	0.604	0.273	0.013*	0.005	0.130
Baseline+GNRI	0.770 (0.716–0.824)	0.874	0.306	0.006*	0.002	0.358
Baseline+SGA	0.779 (0.726–0.832)	0.259	0.344	0.012*	0.002	0.049*

\*P<0.05. Baseline model included age, BMI, SBP, eGFR, and serum sodium. CONUT, controlling nutritional status; GNRI, geriatric nutritional index; IDI, integrated discrimination improvement; NRI, net reclassification improvement; PNI, prognostic nutrition index; SGA, subjective global assessment. Other abbreviations as in Table 1.

an independent predictor in patients with chronic heart failure.<sup>30</sup> SGA has also been suggested to be a useful nutritional screening tool for chronic heart failure.<sup>31</sup> SGA is an indicator that considers both malnutrition and sarcopenia. This simple score enables all medical staff to evaluate comprehensive nutritional status easily.<sup>8</sup> Moreover, this assessment does not change with timing, indicating sufficient reproducibility. Therefore, SGA might have the greatest advantage because it can be evaluated using only subjective assessments.

In chronic heart failure, nutrition occupies an important position. Stratifying nutrition status at hospital admission in patients with ADHF can lead to an early response by a nutrition support team (NST) and a multifaceted approach, such as cardiac rehabilitation from the acute phase of

hospitalization. Taken together, this could reduce the poor prognosis of ADHF.

### Study Limitations

This study had several limitations. First, it involved only a small number of enrolled patients and was conducted at a single center. Second, nutritional screening also differs depending on the etiology of heart failure. It was difficult, however, to analyze the data for each etiology of death because of the small number of enrolled patients. As a result, larger sample sizes and multicenter studies are needed. Finally, we evaluated these nutrition indexes only at hospital admission. Additional screening should be done during the hospital stay or at discharge.

## Conclusions

Nutrition screening at hospital admission might improve the prediction of 1-year mortality in hospitalized patients with ADHF. Nutrition screening at hospital admission could be useful for the stratification of ADHF patients.

## Acknowledgment

We are grateful to the staff at Kasugai Municipal Hospital for their assistance in collecting the medical data.

## Disclosures

H.I. received lecture fees from Astellas Pharma, Bayer Pharmaceutical, Daiichi-Sankyo Pharms, and MSD. T.M. received lecture fees from Bayer Pharmaceutical, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Kowa, MSD, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Novartis Pharma, Pfizer Japan, Sanofi-aventis, and Takeda Pharmaceutical. T.M. also received unrestricted research grant for Department of Cardiology, Nagoya University Graduate School of Medicine from Astellas Pharma, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Kowa, MSD, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Novartis Pharma, Otsuka Pharma, Pfizer Japan, Sanofi-aventis, Takeda Pharmaceutical, and Teijin Pharma. The other authors declare no conflicts of interest.

## References

- Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, et al. Quantifying the heart failure epidemic: Prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. *Eur Heart J* 2004; **25**: 1614–1619.
- Okura Y, Ramadan MM, Ohno Y, Mitsuma W, Tanaka K, Ito M, et al. Impending epidemic: Future projection of heart failure in Japan to the year 2055. *Circ J* 2008; **72**: 489–491.
- Kalantar-Zadeh K, Anker SD, Horwich TB, Fonarow GC. Nutrition and anti-inflammatory interventions in chronic heart failure. *Am J Cardiol* 2008; **101**: 89E–103E.
- Anker SD, Negassa A, Afzal R, Poole-Wilson PA, Cohn JN, Yusuf S. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study. *Lancet* 2003; **361**: 1077–1083.
- Ambrosy AP, Vaduganathan M, Huffman MD, Khan S, Kwasny MJ, Fought AJ, et al. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: An analysis of the EVEREST trial. *Eur J Heart Fail* 2012; **14**: 302–311.
- World Health Organization. Haemoglobin concentrations for the diagnosis of anemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva, 2011.
- Ignacio de Ulibarri J, González-madroño A, de Villar NG, González P, González B, Mancha A, et al. CONUT: A tool for controlling nutritional status. First validation in a hospital population. *Nutr Hosp* 2005; **20**: 38–45.
- Alvares-da-Silva MR, Reverbel da Silveira T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. *Nutrition* 2005; **21**: 113–117.
- Cereda E, Pedrollo C. The geriatric nutritional risk index. *Curr Opin Clin Nutr Metab Care* 2009; **12**: 1–7.
- Detsky AS, Smalley PS, Chang J. Is this patient malnourished? *JAMA* 1994; **271**: 54–58.
- Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Yokota T, Goto K, et al. Body mass index is an independent predictor of long-term outcomes in patients hospitalized with heart failure in Japan. *Circ J* 2010; **74**: 2605–2611.
- Hülsman M, Quittan M, Berger R, Crevenna R, Springer C, Nuhr M, et al. Muscle strength as a predictor of long-term survival

- in severe congestive heart failure. *Eur J Heart Fail* 2004; **6**: 101–107.
- Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as an independent risk factor for mortality in chronic heart failure. *Lancet* 1997; **349**: 1050–1053.
- Fülster S, Tacke M, Sandek A, Ebner N, Tschöpe C, Doehner W, et al. Muscle wasting in patients with chronic heart failure: Results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). *Eur Heart J* 2013; **34**: 512–519.
- Weiss CO. Frailty and chronic diseases in older adults. *Clin Geriatr Med* 2011; **27**: 39–52.
- Horwich TB, Kalantar-Zadeh K, MacLellan RW, Fonarow GC. Albumin levels predict survival in patients with systolic heart failure. *Am Heart J* 2008; **155**: 883–889.
- Bonilla-Palomas JL, Gámez-López AL, Conde MM, Ibáñez CL, Anguita-Sánchez MP, Castillo-Domínguez JC, et al. Malnutrition detected during hospitalization increases re-entry risk in patients with cardiac insufficiency (abstract). *Rev Esp Cardiol* 2011; **64**(Suppl 3): 116 (in Spanish).
- Bonilla-Palomas JL, Gámez-López AL, Anguita-Sánchez MP, Castillo-Domínguez JC, García-Fuertes D, Crespin-Crespin M, et al. Impact of malnutrition on long-term mortality in hospitalized patients with heart failure. *Rev Esp Cardiol* 2011; **64**: 752–758.
- Don BR, Kaysen G. Serum albumin: Relationship to inflammation and nutrition. *Semin Dial* 2004; **17**: 432–437.
- Fuhrman MP, Charney P, Muller CM. Hepatic proteins and nutrition assessment. *J Am Diet Assoc* 2004; **104**: 1258–1264.
- De Feo P, Lucidi P. Liver protein synthesis in physiology and in disease states. *Curr Opin Clin Nutr Metab Care* 2002; **5**: 47–50.
- Ommen SR, Hodge DO, Rodeheffer RJ, McGregor CJ, Thomson SP, Gibbons RJ. Predictive power of the relative lymphocyte concentration in patients with advanced heart failure. *Circulation* 1998; **97**: 19–22.
- Huehnergarth KV, Mozaffarian D, Sullivan MD, Crane BA, Wilkinson CW, Lawler RL, et al. Usefulness of relative lymphocyte count as an independent predictor of death/urgent transplant in heart failure. *Am J Cardiol* 2005; **95**: 1492–1495.
- Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma R, et al. The relationship between cholesterol and survival in patients with chronic heart failure. *J Am Coll Cardiol* 2003; **42**: 1933–1940.
- Edalat-Nejad M, Zameni F, Qlich-Khani M, Salehi F. Geriatric nutritional risk index: A mortality predictor in hemodialysis patients. *Saudi J Kidney Dis Transpl* 2015; **26**: 302–308.
- Narumi T, Arimoto T, Funayama A, Kadowai S, Otaki Y, Nishiyama S, et al. The prognostic importance of objective nutritional indexes in patients with chronic heart failure. *J Cardiol* 2013; **62**: 307–313.
- Sungrutekin H, Sungrutekin U, Hanci V, Erdem E. Comparison of two nutrition assessment techniques in hospitalized patients. *Nutrition* 2004; **20**: 428–432.
- Sheean PM, Petreson SJ, Gomez Perez S, Troy KL, Patel A, Sclamborg JS, et al. The prevalence of sarcopenia in patients with respiratory failure classified as normally nourished using computed tomography and subjective global assessment. *J Parenter Enteral Nutr* 2014; **38**: 873–879.
- Kim JK, Choi SR, Choi MJ, Kim SG, Lee YK, Noh JW, et al. Prevalence of and factors associated with sarcopenia in elderly patients with end-stage renal disease. *Clin Nutr* 2014; **33**: 64–68.
- Narumi T, Watanabe T, Kadowaki S, Takahashi T, Yokoyama M, Kinoshita D, et al. Sarcopenia evaluated by fat-free mass index is an important prognostic factor in patients with chronic heart failure. *Eur J Intern Med* 2015; **26**: 118–122.
- Guerra-Sánchez L, Martínez-Rincón C, Fresno-Flores M. Prevalence of undernutrition in hospital patients with unbalanced heart failure; subjective global assessment like prognosis sign. *Nutr Hosp* 2015; **31**: 1754–1762.

## Supplementary Files

Please find supplementary file(s);  
<http://dx.doi.org/10.1253/circrep.CR-18-0018>